Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice.
BMC Psychiatry 2019; 19(1):393BP

Abstract

BACKGROUND

The purpose of this study was to assess the pharmacological treatment strategies of inpatients with borderline personality disorder between 2008 and 2012. Additionally, we compared pharmacotherapy during this period to a previous one (1996 to 2004).

METHODS

Charts of 87 patients with the main diagnosis of borderline personality disorder receiving inpatient treatment in the University Medical Center of Goettingen, Germany, between 2008 and 2012 were evaluated retrospectively. For each inpatient treatment, psychotropic drug therapy including admission and discharge medication was documented. We compared the prescription rates of the interval 2008-2012 with the interval 1996-2004.

RESULTS

94% of all inpatients of the interval 2008-2012 were treated with at least one psychotropic drug at time of discharge. All classes of psychotropic drugs were applied. We found high prescription rates of naltrexone (35.6%), quetiapine (19.5%), mirtazapine (18.4%), sertraline (12.6%), and escitalopram (11.5%). Compared to 1996-2004, rates of low-potency antipsychotics, tri-/tetracyclic antidepressants and mood stabilizers significantly decreased while usage of naltrexone significantly increased.

CONCLUSIONS

In inpatient settings, pharmacotherapy is still highly prevalent in the management of BPD. Prescription strategies changed between 1996 and 2012. Quetiapine was preferred, older antidepressants and low-potency antipsychotics were avoided. Opioid antagonists are increasingly used and should be considered for further investigation.

Authors+Show Affiliations

Department of Psychiatry and Psychotherapy, University Medical Centre, University of Goettingen, Von-Siebold-Straβe 5, 37075, Goettingen, Germany. charles.timaeus@med.uni-goettingen.de.Department of Psychiatry and Psychotherapy, University Medical Centre, University of Goettingen, Von-Siebold-Straβe 5, 37075, Goettingen, Germany.Department of Psychiatry and Psychotherapy, University Medical Centre, University of Goettingen, Von-Siebold-Straβe 5, 37075, Goettingen, Germany.Department of Psychiatry and Psychotherapy, University Medical Centre, University of Goettingen, Von-Siebold-Straβe 5, 37075, Goettingen, Germany.Department of Psychiatry and Psychotherapy, University Medical Centre, University of Goettingen, Von-Siebold-Straβe 5, 37075, Goettingen, Germany.Department of Psychiatry and Psychotherapy, University Medical Centre, University of Goettingen, Von-Siebold-Straβe 5, 37075, Goettingen, Germany. German Center for Neurodegenerative Diseases, Goettingen, Germany. Institute for Research in Biomedicine, Medical Science Department, University of Aveiro, Aveiro, Portugal.Department of Psychiatry and Psychotherapy, University Medical Centre, University of Goettingen, Von-Siebold-Straβe 5, 37075, Goettingen, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31830934

Citation

Timäus, Charles, et al. "Pharmacotherapy of Borderline Personality Disorder: what Has Changed Over Two Decades? a Retrospective Evaluation of Clinical Practice." BMC Psychiatry, vol. 19, no. 1, 2019, p. 393.
Timäus C, Meiser M, Bandelow B, et al. Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry. 2019;19(1):393.
Timäus, C., Meiser, M., Bandelow, B., Engel, K. R., Paschke, A. M., Wiltfang, J., & Wedekind, D. (2019). Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry, 19(1), p. 393. doi:10.1186/s12888-019-2377-z.
Timäus C, et al. Pharmacotherapy of Borderline Personality Disorder: what Has Changed Over Two Decades? a Retrospective Evaluation of Clinical Practice. BMC Psychiatry. 2019 Dec 12;19(1):393. PubMed PMID: 31830934.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. AU - Timäus,Charles, AU - Meiser,Miriam, AU - Bandelow,Borwin, AU - Engel,Kirsten R, AU - Paschke,Anne M, AU - Wiltfang,Jens, AU - Wedekind,Dirk, Y1 - 2019/12/12/ PY - 2019/07/04/received PY - 2019/11/27/accepted PY - 2019/12/14/entrez PY - 2019/12/14/pubmed PY - 2019/12/14/medline KW - Borderline personality disorder KW - Comorbidity KW - Pharmacotherapy SP - 393 EP - 393 JF - BMC psychiatry JO - BMC Psychiatry VL - 19 IS - 1 N2 - BACKGROUND: The purpose of this study was to assess the pharmacological treatment strategies of inpatients with borderline personality disorder between 2008 and 2012. Additionally, we compared pharmacotherapy during this period to a previous one (1996 to 2004). METHODS: Charts of 87 patients with the main diagnosis of borderline personality disorder receiving inpatient treatment in the University Medical Center of Goettingen, Germany, between 2008 and 2012 were evaluated retrospectively. For each inpatient treatment, psychotropic drug therapy including admission and discharge medication was documented. We compared the prescription rates of the interval 2008-2012 with the interval 1996-2004. RESULTS: 94% of all inpatients of the interval 2008-2012 were treated with at least one psychotropic drug at time of discharge. All classes of psychotropic drugs were applied. We found high prescription rates of naltrexone (35.6%), quetiapine (19.5%), mirtazapine (18.4%), sertraline (12.6%), and escitalopram (11.5%). Compared to 1996-2004, rates of low-potency antipsychotics, tri-/tetracyclic antidepressants and mood stabilizers significantly decreased while usage of naltrexone significantly increased. CONCLUSIONS: In inpatient settings, pharmacotherapy is still highly prevalent in the management of BPD. Prescription strategies changed between 1996 and 2012. Quetiapine was preferred, older antidepressants and low-potency antipsychotics were avoided. Opioid antagonists are increasingly used and should be considered for further investigation. SN - 1471-244X UR - https://www.unboundmedicine.com/medline/citation/31830934/Pharmacotherapy_of_borderline_personality_disorder:_what_has_changed_over_two_decades_A_retrospective_evaluation_of_clinical_practice L2 - https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2377-z DB - PRIME DP - Unbound Medicine ER -